Study Finds Shortage of Medical Geneticists
How will oncology deal with a lack of medical genetics professionals to help treat cancer with precision genomic medicine?
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Analysis Highlights Link Between Lymphoma and Glyphosate
EPA panelists, frustrated with the agency’s review process, publish their own analysis implicating the controversial herbicide’s role in non-Hodgkin lymphoma risk. -
Multiple Myeloma and Infections: Characterizing the Risks
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged. -
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency -
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
HEMATOLOGIC CANCER NEWS
Two Measures Independently Predict for NHL in Patients With HIV
Contrast-Enhanced MRI Characterization of Brain Cancers
Poor Outcome for Patients With Multiple Myeloma Who Are Refractory to CD38-Targeting Agent
Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
Managing Neutropenic Sepsis in Patients With Cancer
MORE HEMATOLOGIC CANCER INFORMATION
A 47-Year-Old Woman with Pancytopenia After Treatment with Radioiodine Therapy
DARZALEX (daratumumab) for Multiple Myeloma
ZOLINZA (vorinostat) for Cutaneous T-cell Lymphoma
NINLARO (ixazomib) for Multiple Myeloma
GAZYVA (obinutuzumab) for Follicular Lymphoma
VENCLEXTA (venetoclax) for Chronic Lymphocytic Leukemia
EMPLICITI (elotuzumab) for Multiple Myeloma
SPRYCEL (dasatinib) for Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
